Medtronic plc — FY2024 Form 10-K Summary
Business context and reporting period
Medtronic is a global medical technology company operating across Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. This is an annual report for the fiscal year ended April 26, 2024—not a standalone 2023 fourth-quarter filing. Comparisons below are with the fiscal year ended April 28, 2023. Amounts are in U.S. dollars.
Financial results and liquidity
| Metric | FY2024 | FY2023 | Change |
|---|---|---|---|
| Net sales | $32.364 billion | $31.227 billion | Up 4% |
| Operating profit | $5.144 billion | $5.485 billion | Down 6% |
| Operating margin | 15.9% | 17.6% | Down 1.7 percentage points |
| Net income attributable to Medtronic | $3.676 billion | $3.758 billion | Down 2% |
| Diluted GAAP EPS | $2.76 | $2.82 | Down 2% |
| Operating cash flow | $6.787 billion | $6.039 billion | Up $748 million |
| Free cash flow (non-GAAP) | $5.200 billion | $4.580 billion | Up $620 million |
Revenue growth reflected gains in most businesses and international markets. By reportable segment, sales were Cardiovascular $11.831 billion (up 3%), Neuroscience $9.406 billion (up 5%), Medical Surgical $8.417 billion (up 5%), and Diabetes $2.488 billion (up 10%). Diabetes growth was driven largely by MiniMed 780G expansion; Cardiovascular growth included Micra, TAVR, and perfusion products.
GAAP gross profit margin, calculated using cost of products sold and separately reported intangible amortization, is not presented as a single measure in the supplied filing text. Cost of products sold was $11.216 billion, while R&D was $2.735 billion and SG&A was $10.736 billion. Non-GAAP diluted EPS was $5.20 versus $5.29 in FY2023; non-GAAP measures exclude specified adjustments and are not substitutes for GAAP results.
At year-end, cash and cash equivalents were $1.284 billion and current investments were $6.721 billion. Total debt was approximately $25.0 billion, compared with $24.4 billion a year earlier. The company had $1.073 billion of commercial paper outstanding, no borrowings under its $3.5 billion revolving credit facility, and reported compliance with facility covenants. Current assets were $21.935 billion and current liabilities $10.789 billion. Dividends paid were $3.666 billion; share repurchases were approximately 25 million shares for $2.138 billion of cash outflow.
Material changes and unusual items
- Operating profit fell despite higher sales, with cost inflation and higher operating expenses among the pressures. Net sales in FY2023 included a $265 million one-time payment under an intellectual property agreement with Edwards Lifesciences, affecting year-over-year Cardiovascular comparisons.
- In February 2024, Medtronic decided to exit its ventilator product line and retain and combine the remaining patient monitoring and respiratory businesses. It recorded $439 million of pretax charges, including $295 million of intangible-asset impairments and $70 million of inventory write-downs. The company said it would honor existing ventilator contracts.
- FY2024 included $308 million of net losses on minority investments, including a $220 million reduction in the fair value of the retained Mozarc Medical investment. The Israeli tax court decision concerning an alleged taxable transfer of intellectual property resulted in a $187 million tax charge; Medtronic appealed.
- Restructuring and associated costs were $389 million in FY2024. A $149 million net litigation charge was recorded, compared with $30 million of litigation income in FY2023.
Outlook, risks, and contingencies
The filing discusses expected growth from product launches, pipeline development, international expansion, and innovation, but does not provide a clear quantified company-wide FY2025 revenue or EPS forecast in the supplied text. Management identifies risks including competition and pricing pressure, reimbursement changes, clinical or regulatory delays, product quality and liability matters, supply interruptions, cybersecurity and privacy incidents, foreign exchange, inflation, geopolitical disruption, and healthcare cost containment. China tender pricing and competition from GLP-1 drugs are among the cited market pressures.
Medtronic reported approximately 8,350 individual plaintiffs in hernia mesh litigation and 107 plaintiffs in insulin-pump retainer-ring lawsuits as of the dates stated in the filing; it said losses were not currently probable and reasonably estimable. A jury verdict of approximately $106 million in the Colibri patent case was under appeal, and the company had not accrued an expense because it did not consider a loss probable. The Puerto Rico IRS income-allocation dispute remained on appeal; the auditor identified the related uncertain tax position as a critical audit matter. Gross unrecognized tax benefits were $2.824 billion at year-end.
The company stated that its balance sheet and liquidity should meet foreseeable operating needs. It also disclosed that global minimum tax rules under OECD Pillar Two are expected to apply from FY2025 and that it was still evaluating their effects. A $3.0 billion euro-denominated notes issuance completed after year-end, on June 3, 2024.
Investor facts to verify
- Review the full GAAP-to-non-GAAP reconciliations and assess whether recurring adjustments, including amortization and restructuring, change the interpretation of earnings trends.
- Track segment growth and margins, particularly Diabetes and Cardiovascular, and test whether new products sustain demand and offset pricing and competitive pressures.
- Assess the cash and debt position alongside debt maturities, commercial paper use, dividends, and continued share repurchases.
- Follow outcomes and potential cash effects of the Puerto Rico tax appeal, Israeli tax appeal, and material product-liability and intellectual-property matters.
- Monitor execution and financial effects of the ventilator exit, including remaining obligations and any further charges.